|
| Index | - | P/E | - | EPS (ttm) | -1.54 | Insider Own | 1.40% | Shs Outstand | 12.93M | Perf Week | -8.45% |
| Market Cap | 181.40M | Forward P/E | - | EPS next Y | -1.86 | Insider Trans | 0.56% | Shs Float | 9.52M | Perf Month | 25.78% |
| Income | -19.30M | PEG | - | EPS next Q | -0.56 | Inst Own | 83.50% | Short Float | 1.48% | Perf Quarter | 7.73% |
| Sales | - | P/S | - | EPS this Y | -170.50% | Inst Trans | 10.50% | Short Ratio | 0.73 | Perf Half Y | 8.33% |
| Book/sh | 6.26 | P/B | 2.18 | EPS next Y | 7.50% | ROA | - | Target Price | - | Perf Year | - |
| Cash/sh | 6.14 | P/C | 2.22 | EPS next 5Y | -4.80% | ROE | - | 52W Range | 8.76 - 22.00 | Perf YTD | 19.82% |
| Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | - | 52W High | -37.91% | Beta | - |
| Dividend % | - | Quick Ratio | 17.70 | Sales past 5Y | - | Gross Margin | - | 52W Low | 55.93% | ATR | 1.01 |
| Employees | 38 | Current Ratio | 17.70 | Sales Q/Q | - | Oper. Margin | - | RSI (14) | 52.38 | Volatility | 8.32% 7.07% |
| Optionable | No | Debt/Eq | 0.00 | EPS Q/Q | -43.20% | Profit Margin | - | Rel Volume | 0.56 | Prev Close | 14.03 |
| Shortable | Yes | LT Debt/Eq | 0.00 | Earnings | Mar 09 AMC | Payout | - | Avg Volume | 191.76K | Price | 13.66 |
| Recom | 1.00 | SMA20 | 1.53% | SMA50 | 13.60% | SMA200 | 11.26% | Volume | 107,316 | Change | -2.64% |
 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210 and LYR-220, which are bioresorbable polymeric matrices for the treatment of chronic rhinosinusitis. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was founded in 2005 and is headquartered in Watertown, Massachusetts. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
| open in yahoo | open in reuters | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite